Picture of VBI Vaccines logo

VBIV VBI Vaccines Share Price

0.000.00%
us flag iconLast trade - 00:00
HealthcareSpeculativeMicro CapNeutral

Momentum

Relative Strength (%)
1m-11.41%
3m-4.6%
6m-28.01%
1yr-95.08%
Volume Change (%)
10d/3m-45.37%
Price vs... (%)
52w High-94.51%
50d MA-6.31%
200d MA-40.07%

Growth & Value

Shareholder Activity

TypeBuy / Hold / Sell
Institutions
Directors
Community

Guru Screens

Quality

NameIndustryMarket
Return on Capital-372.99%
Return on Equity-221.45%
Operating Margin-1083.34%

Health Trend(F-Score)

12345678910

Bankruptcy Score(Z-Score)

Distress
Cautious
Safe

Earnings Manipulation Risk(M-Score)

Other Ratios

Leverage (ttm)Total- Intang+ Pension
Gross Gearing
Net Gearing
Cash / Assets

Recent History

Latest interim period vs. prior periodIndustryMarket
Sales Growth
EPS Growth
3yr Compound Annual Growth RateIndustryMarket
Sales CAGR
EPS CAGR
DPS CAGR

Graphical History

Revenue
Blurred out image of Revenue chart
Net Income
Blurred out image of Net Income chart
Normalised EPS
Blurred out image of Normalised EPS chart
PE Ratio Range
Blurred out image of PE Ratio Range chart
Dividend Yield Range
Blurred out image of Dividend Yield Range chart

Analyst Forecasts

Price target
( price)
31st Dec 202331st Dec 2024
Est. Long Term Growth Rate: Net Profit
()
EPS
()
DPS
()
Net Profit
()
EPS
()
DPS
()
Consensus Estimate
1m Change
3m Change

Analyst Consensus

Strong SellSellHoldBuyStrong Buy

EPS 2023 / 2024

Blurred out image of VBI Vaccines EPS forecast chart

Profile Summary

VBI Vaccines Inc. is a commercial stage biopharmaceutical company. Through its approach to virus-like particles (VLPs), including an enveloped VLP (eVLP) platform technology, The Company develops vaccine candidates that mimic the natural presentation of viruses, designed to elicit the innate power of the human immune system. The Company is focused on targeting and overcoming infectious diseases, including hepatitis B (HBV), COVID-19, and coronaviruses, and cytomegalovirus (CMV), as well as cancers, including glioblastoma (GBM). Its product pipeline includes an approved vaccine and multiple late- and early-stage investigational programs. PreHevbrio is its approved vaccine for hepatitis B. Its Prophylactic Candidates for corona virus disease include VBI-2901, VBI-2905, VBI-2902, and other. VBI-1501 is its Prophylactic Candidate for cytomegalovirus. VBI-2501 is its Prophylactic Candidate for Zika virus. VBI-2601 and VBI-1901 are the therapeutic candidates for HBV and GBM.

Directors

Last Annual
December 31st, 2022
Last Interim
September 30th, 2023
Incorporated
May 6th, 2016
Public Since
November 19th, 2001
No. of Shareholders
814
No. of Employees
190
Sector
Biotechnology & Medical Research
Industry
Healthcare
Exchange
us flag iconNASDAQ Capital Market
Shares in Issue
23,687,695

VBIV Share Price Performance

Upcoming Events for VBIV

Q1 2024 VBI Vaccines Inc Earnings Release

VBI Vaccines Inc Annual Shareholders Meeting

Q2 2024 VBI Vaccines Inc Earnings Release

Similar to VBIV

Picture of 180 Life Sciences logo

180 Life Sciences

us flag iconNASDAQ Capital Market

Picture of Abeona Therapeutics logo

Abeona Therapeutics

us flag iconNASDAQ Capital Market

Picture of ABVC Biopharma logo

ABVC Biopharma

us flag iconNASDAQ Capital Market

Picture of Acesis Holdings logo

Acesis Holdings

us flag iconNASDAQ Capital Market

Picture of Achieve Life Sciences logo

Achieve Life Sciences

us flag iconNASDAQ Capital Market

FAQ